Zachary David Hoff sold vials of “GLP-3 Reta (Retatrutide)” from a Sarasota, Florida address, twelve milligrams to a vial, and his website called the material research. On 24 August 2026 the Food and Drug Administration answered him in writing: the vial is a drug, no approved application covers it, and the research label does not change that. If you typed peptides for research into a search bar this week, you walked into the middle of a market the agency has been dismantling on paper for eighteen months, and the paper is public.
The answer in one sentence: a research label covers a laboratory reagent, and it stops covering anything the moment the seller’s own pages describe what the molecule does inside a human body.
The retail trade in research-labeled peptides is a legal fiction with a shipping label. Its own marketing wrote the evidence that ended it.
Peptides for Research – Six Words That Protected Nothing
Federal law decides what a product is by intended use, not by the sticker on the vial. The regulation at 21 CFR 201.128 lets the agency read a company’s website, product pages, bundle offers and marketing claims as evidence of what the seller means the buyer to do with the product.
FDA has applied that reading to peptide sellers at least since 26 February 2025, when its Center for Drug Evaluation and Research wrote to USApeptide.com about semaglutide and tirzepatide vials. That letter contains a sentence worth memorizing: “Despite statements on your product labeling and website such as ‘research use only,’ ‘not for human consumption,’ ‘lab purposes only,’ and ‘not intended to diagnose, cure, mitigate, treat or prevent disease,’ evidence obtained from your website establishes that certain products offered for sale by www.usapeptide.com are drugs intended for human use.”
Eighteen months later the agency used the same construction four times in one day. A disclaimer is a sentence. A product page is a confession.
The Four Letters – FDA Quoted the Sales Copy Back
The letters dated 24 August 2026 that I opened at fda.gov, each following a July 2026 review of the firm’s website, are:
- Reference 735127 to Peak Performance Peptides of Phoenix, Arizona, addressed to founder Jeffrey Deng.
- Reference 734884 to Royal Peptides LLC, addressed to Rocco Abate and Michael Fraunfelter.
- Reference 733652 to NuScience Peptides LLC of Cornelius, North Carolina, addressed to Joseph and Ratsamy DeRosa.
- Reference 735063 to Peptide Partners LLC at a Pirsek Technologies address in Sarasota, Florida, addressed to Zachary David Hoff.
Each letter gives the firm fifteen business days to answer. Each is FDA’s stated position at the time of sending, not a court finding, and each firm can respond. Four firms, four cities, one July of website review, one footnote rebuilt with the names changed.
The evidence FDA pasted into the letters came off the sellers’ own pages. Under the tirzepatide page at Royal Peptides, the agency quoted: “Tirzepatide has become a major focus of metabolic, endocrinology, obesity, and peptide science due to its unique activity at both the GLP-1 and GIP receptors.” Under Peptide Partners’ retatrutide listing, this: “Retatrutide can activate three different hormone receptors in the body that control appetite and metabolism.” Under NuScience’s survodutide listing: preclinical studies “demonstrated its efficacy in promoting weight loss and improving glycemic control.”
Read those three lines again. Each one describes a metabolic effect in a person, and each sat on a page selling a vial for laboratory research.
Bacteriostatic Water – the Cheapest Item in the Cart Made the Case
The detail that recurs in all four letters is the solvent. Peak Performance sold “Bac water.” Royal Peptides sold bacteriostatic water next to a “peptide guide” and a “peptide calculator.” NuScience sold “Bacteriostatic water for Peptides (BAC Water)” next to a “peptide calculator.” Peptide Partners sold “Reconstitution Solution (BAC).”
FDA’s reasoning, quoted from the Peak Performance letter, runs like this: “you market bacteriostatic water as a solvent for reconstituting your products, thus, providing the means to prepare an injectable drug for human administration.”
That is the whole case in one line. A cell-culture lab does not buy a bacteriostatic water bundle with a mixing guide; a lab buys its own reagents. The bundle is a preparation kit for an injection, and the agency treated it as one.
The Peptide Calculator – Our Own Refusal, Vindicated
Two of the four letters name a peptide calculator as evidence of intended human use. We published a page on that calculator on 7 October 2026 and refused to operate it. The arithmetic was accurate, we wrote, and the arithmetic was the least of it: a milligram-to-unit conversion assumes a vial of known concentration, in known condition, made by someone accountable for what is inside it.
FDA made the narrower point, and the narrow point is enough. A calculator that turns a powder into a syringe volume is a tool for preparing an injectable drug. Sell it beside the powder and the powder stops being a laboratory chemical. Our conclusion and the agency’s conclusion arrived from opposite directions, which is what makes the agreement worth something.
Peptides for Research – Nine Named, Two Already Approved
Across the four letters, FDA named nine distinct peptides plus the water: semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31 (elamipretide), PT-141 (bremelanotide), tesamorelin and ipamorelin. The letters also name blends and kit pairings, including a tesamorelin and ipamorelin blend sold under the label BIMORELIN.
Two of those nine already exist as approved prescription drugs, and this is where the story narrows to something a patient can use. Bremelanotide is approved as Vyleesi; the current label in the National Library of Medicine’s DailyMed record carries a publication date of 18 November 2025. Tesamorelin is approved as Egrifta WR and Egrifta SV, with labels published 3 August 2026 and 31 July 2026. Ipamorelin returns zero results in that same database.
The rest have no approved product at all. Retatrutide, survodutide and mazdutide are investigational molecules. Semaglutide and tirzepatide are approved under brand names that require a prescription, which is precisely the step the vial channel exists to skip.
What Is Legal – Three Doors, and None of Them Is a Shopping Cart
FDA’s 503A page sets out what a state-licensed physician or pharmacist may compound with. The bulk substance must meet an applicable USP or National Formulary monograph, or be a component of an FDA-approved drug product, or appear on FDA’s 503A bulks list. It must arrive with a valid certificate of analysis from an establishment registered with the agency.
That page also lists the list’s two actions: a final rule in February 2019 that placed six substances on the list and declined four, and a proposed rule in September 2019 that proposed five on and 26 off. Separate FDA guidance is blunt about the products themselves: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they reach a patient.
Put plainly, the lawful paths are a prescription for an approved product from a state-licensed pharmacy, or a compounded product from a licensed pharmacy working inside 503A for a patient whose medical need an approved drug cannot meet. The lawful road is slower, involves a clinician, and produces a label with a dose on it. That is the point of it.
What the Letters Do Not Say
Honesty matters more here than drama, so here is the boundary of the record I read.
The four letters do not allege that the vials were contaminated, understrength or mislabeled. They allege unapproved and misbranded drugs, and in three of the four, sale without a prescription. FDA reported no laboratory testing of these products in these letters. A warning letter is an allegation with a reference number, not a verdict.
The agency’s own harm numbers are incomplete by design. Its page on unapproved GLP-1 drugs reports 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of 31 May 2026, and then says why the figures understate the problem: federal law does not require state-licensed pharmacies that are not outsourcing facilities to report. Some of the reported events involved dosing errors and hospital care.
I could not verify a contamination rate for this sales channel at any primary source, and I am not going to invent one. Silence about quality is not a clean bill. It is silence, and the buyer carries it.
Frequently asked questions
Are peptides for research legal to buy?
Selling a substance as a laboratory reagent is a lawful business. Selling it as a drug without approval is not, and FDA decides which one a seller is doing from the seller’s own claims, bundles and instructions. The four August 2026 letters show the agency reading product pages and calculators as evidence of human use, whatever the disclaimer said.
What does “for research use only” mean on a peptide vial?
It means the seller asserts the material is for laboratory work, not for a person. FDA’s position, stated in these letters, is that the assertion does not control when the website around it describes human effects or sells the means to inject. Our longer treatment sits in Peptides Explained.
Did FDA ban research peptides?
No. There is no ban and no new rule in these letters. FDA enforced the existing rule that a new drug needs an approved application, and sent four firms a warning with fifteen business days to answer.
Can I still get a peptide with a prescription?
Yes, for the peptides that have approved products. Bremelanotide is approved as Vyleesi and tesamorelin as Egrifta WR and Egrifta SV, both prescription drugs dispensed by a licensed pharmacy. Compounding under 503A remains available for a patient whose medical need an approved drug cannot meet.
Is a compounded peptide the same as the approved drug?
Not automatically. FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. A compounded product can contain the same active ingredient as an approved drug and still differ in strength, purity and handling.
Why does bacteriostatic water keep appearing in FDA warning letters?
Because it turns a powder into an injection. FDA reads the solvent, the mixing guide and the calculator as a preparation kit, and a preparation kit establishes that the seller expects a human to use the product. It appeared in all four letters dated 24 August 2026.
Are these warning letters proof that the products were unsafe?
No, and this is the part worth holding carefully. The letters allege unapproved and misbranded drugs. They do not report testing that showed contamination or wrong potency. The record does establish that the material reached buyers without an approval, without a prescribed dose and without a pharmacist in the chain.
Sources: FDA Warning Letter, Peak Performance Peptides, 24 August 2026, FDA Warning Letter, Royal Peptides LLC, 24 August 2026, FDA Warning Letter, NuScience Peptides LLC, 24 August 2026, FDA Warning Letter, Peptide Partners LLC, 24 August 2026, FDA Warning Letter, USApeptide.com, 26 February 2025, FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA, Bulk Drug Substances Used in Compounding Under Section 503A, DailyMed, Vyleesi (bremelanotide) label, published 18 November 2025, DailyMed, Egrifta WR (tesamorelin) label, published 3 August 2026.